TABLE 4.
CTRCD rates at different time points stratified by the HFA‐ICOS score and LVTFD‐based score.
| CTRCD rates (derivation cohort) | CTRCD rates (validation cohort) | |||||
|---|---|---|---|---|---|---|
| Variable | At 1 year | At 2 years | At the end of follow‐up time | At 1 year | At 2 years | At the end of follow‐up time |
| HFA‐ICOS score | ||||||
| Low risk | 11/172 (6.4%) | 19/172 (11.0%) | 22/172 (12.8%) | 7/114 (6.4%) | 10/114 (8.8%) | 12/114 (10.5%) |
| Moderate risk | 11/35 (31.4%) | 13/35 (34.3%) | 14/35 (40.0%) | 7/25 (28.0%) | 11/25 (44.0%) | 12/25 (48.0%) |
| High risk | 4/15 (26.7%) | 8/15 (53.3%) | 8/15 (53.3%) | 3/9 (33.3%) | 5/9 (55.6%) | 5/9 (55.6%) |
| Very high risk | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) | 0/0 (0%) |
| LVTFD‐based score | ||||||
| Low risk (0–1 point) | 7/118 (5.9%) | 9/118 (7.6%) | 12/118 (10.1%) | 4/80 (5.0%) | 5/80 (6.3%) | 8/80 (10.3%) |
| Moderate risk (2–3 points) | 13/87 (14.9%) | 21/87 (24.1%) | 22/87 (25.3%) | 9/56 (16.1%) | 14/56 (25.0%) | 14/56 (25.0%) |
| High risk (≥4 points) | 6/17 (35.3%) | 10/17 (58.8%) | 10/17 (58.8%) | 4/12(33.3%) | 7/12 (58.3%) | 7/12 (58.3%) |
Abbreviations: CTRCD, cancer therapy–related cardiac dysfunction; HFA‐ICOS, Heart Failure Association–International Cardio‐Oncology Society; LVTFD, left ventricular trabecular fractal dimension.